title: Investigator ratings of ADHD symptoms during a randomized, placebo-controlled trial of atomoxetine: a comparison of parents and teachers as informants.
abstract: This study compared investigator ratings of ADHD symptoms based on interviews with parents and teachers during a doubleblind, placebo-controlled study of atomoxetine. Investigators completed the ADHD Rating Scale: Investigator (ADHDRS-I) based on separate semistructured interviews with the primary caretaker and teacher of the participant. Interviews were conducted at Visits 2 to 7 during a double-blind treatment protocol comparing atomoxetine (N= 10) and placebo (N= 6). Both parent and teacher-based ratings were sensitive to change in ADHD symptoms with atomoxetine treatment. Parent-based assessment differentiated significantly between treatment with atomoxetine and placebo, whereas teacher-based assessment was less sensitive to change. Parents and teachers showed good agreement on change in ADHDRS-I scores. Investigator ratings based on parent- and teacher-report were sensitive to change in symptoms of ADHD during treatment with atomoxetine. Despite good agreement between parent- and teacher-based ratings of symptom change, parent-based ADHD symptom ratings are more sensitive to symptom change.
authors.affiliation: Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
authors.forename: Bradley N
authors.initials: BN
authors.lastname: Bohnstedt
authors.forename: William G
authors.initials: WG
authors.lastname: Kronenberger
authors.forename: David W
authors.initials: DW
authors.lastname: Dunn
authors.forename: Ann L
authors.initials: AL
authors.lastname: Giauque
authors.forename: Elisabeth A
authors.initials: EA
authors.lastname: Wood
authors.forename: Mary E
authors.initials: ME
authors.lastname: Rembusch
authors.forename: Deborah
authors.initials: D
authors.lastname: Lafata
mesh_terms: D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*; D002648:Child; D004311:Double-Blind Method; D005178:Faculty; D005260:Female; D006801:Humans; D008297:Male; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D015588:Observer Variation; D010290:Parents; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use*; D011569:Psychiatric Status Rating Scales
chemical_list: D011437:Propylamines; D000069445:Atomoxetine Hydrochloride; D009638:Norepinephrine